EcoDrugPlus

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSPNAG00000009981
Gene Symbol: GRIK5
3 Cross references
229 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSPNAG00000020554
Gene Symbol: GRIK5
3 Cross references
232 Possible Orthologues:

Glutamate Metabotropic Receptor 2

Ensembl ID : ENSPNAG00000015964
Gene Symbol: GRM2
3 Cross references
207 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSPNAG00000014851
Gene Symbol: GRM4
3 Cross references
206 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSPNAG00000010408
Gene Symbol: GRM4
3 Cross references
206 Possible Orthologues:

Glutamate Receptor 1-Like

Ensembl ID : ENSPNAG00000011558
Gene Symbol: LOC108439760
3 Cross references
249 Possible Orthologues:

Glutamate Receptor 1-Like

Ensembl ID : ENSPNAG00000020218
Gene Symbol: LOC108427845
3 Cross references
251 Possible Orthologues:

Glutamate Receptor 2

Ensembl ID : ENSPNAG00000015038
Gene Symbol: LOC108411138
3 Cross references
225 Possible Orthologues:

Glutamate Receptor 2-Like

Ensembl ID : ENSPNAG00000006262
Gene Symbol: LOC108443988
3 Cross references
242 Possible Orthologues:

Glutamate Receptor 3-Like

Ensembl ID : ENSPNAG00000008780
Gene Symbol: LOC108413172
3 Cross references
175 Possible Orthologues:

Glutamate Receptor 4

Ensembl ID : ENSPNAG00000003456
Gene Symbol: LOC108440167
3 Cross references
252 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 1

Ensembl ID : ENSPNAG00000004430
Gene Symbol: LOC108435476
3 Cross references
206 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).